BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 8725138)

  • 1. Cytologic effects of photodynamic therapy in body fluids.
    Garza OT; Abati A; Sindelar WF; Pass HI; Hijazi YM
    Diagn Cytopathol; 1996 Jun; 14(4):356-61. PubMed ID: 8725138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytopathologic differential diagnosis of malignant mesothelioma, adenocarcinoma and reactive mesothelial cells: A logistic regression analysis.
    Cakir E; Demirag F; Aydin M; Unsal E
    Diagn Cytopathol; 2009 Jan; 37(1):4-10. PubMed ID: 18973123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraoperative photodynamic therapy of the chest cavity in malignant pleural mesothelioma bearing rats.
    Krueger T; Pan Y; Tran N; Altermatt HJ; Opitz I; Ris HB
    Lasers Surg Med; 2005 Oct; 37(4):271-7. PubMed ID: 16245295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cell adhesion molecule, E-cadherin, distinguishes mesothelial cells from carcinoma cells in fluids.
    Schofield K; D'Aquila T; Rimm DL
    Cancer; 1997 Oct; 81(5):293-8. PubMed ID: 9349517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT; Gentile P; Tarectecan A; Fuchs A
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.
    Illei PB; Ladanyi M; Rusch VW; Zakowski MF
    Cancer; 2003 Feb; 99(1):51-6. PubMed ID: 12589646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buried Barrett's epithelium following photodynamic therapy shows reduced crypt proliferation and absence of DNA content abnormalities.
    Hornick JL; Mino-Kenudson M; Lauwers GY; Liu W; Goyal R; Odze RD
    Am J Gastroenterol; 2008 Jan; 103(1):38-47. PubMed ID: 18076737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
    Ylagan LR; Zhai J
    Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic utility of D2-40 and podoplanin in effusion cell blocks.
    Bhalla R; Siddiqui MT; Mandich D; Cartun RW; Fiel-Gan MD; Nassar A; Mandavilli SR
    Diagn Cytopathol; 2007 Jun; 35(6):342-7. PubMed ID: 17497664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infection of mesothelial cells with human herpes virus 8 in human immunodeficiency virus-infected patients with Kaposi's sarcoma, Castleman's disease, and recurrent pleural effusions.
    Bryant-Greenwood P; Sorbara L; Filie AC; Little R; Yarchoan R; Wilson W; Raffeld M; Abati A
    Mod Pathol; 2003 Feb; 16(2):145-53. PubMed ID: 12591967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diagnostic yield of pleural fluid cytology in malignant pleural effusions.
    Ong KC; Indumathi V; Poh WT; Ong YY
    Singapore Med J; 2000 Jan; 41(1):19-23. PubMed ID: 10783675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions.
    Holloway AJ; Diyagama DS; Opeskin K; Creaney J; Robinson BW; Lake RA; Bowtell DD
    Clin Cancer Res; 2006 Sep; 12(17):5129-35. PubMed ID: 16951230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytologic criteria used to diagnose adenocarcinoma in pleural effusions.
    Bottles K; Reznicek MJ; Holly EA; Ahn DK; Layfield LJ; Cohen MB
    Mod Pathol; 1991 Nov; 4(6):677-81. PubMed ID: 1788258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Buried dysplasia and early adenocarcinoma arising in barrett esophagus after porfimer-photodynamic therapy.
    Mino-Kenudson M; Ban S; Ohana M; Puricelli W; Deshpande V; Shimizu M; Nishioka NS; Lauwers GY
    Am J Surg Pathol; 2007 Mar; 31(3):403-9. PubMed ID: 17325482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.
    Afify AM; Stern R; Michael CW
    Diagn Cytopathol; 2005 Mar; 32(3):145-50. PubMed ID: 15690337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Photodynamic therapy as an adjunct to surgery for malignant pleural mesothelioma.
    Ris HB
    Lung Cancer; 2005 Jul; 49 Suppl 1():S65-8. PubMed ID: 15916831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Photodynamic therapy as an innovative treatment for malignant pleural mesothelioma.
    Friedberg JS
    Semin Thorac Cardiovasc Surg; 2009; 21(2):177-87. PubMed ID: 19822291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serous effusions in malignant lymphomas: a review.
    Das DK
    Diagn Cytopathol; 2006 May; 34(5):335-47. PubMed ID: 16604559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignant-appearing cells in pleural effusion due to pancreatitis: case report and literature review.
    Kutty CP; Remeniuk E; Varkey B
    Acta Cytol; 1981; 25(4):412-6. PubMed ID: 6945008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental photodynamic therapy for malignant pleural mesothelioma with pegylated mTHPC.
    Krueger T; Altermatt HJ; Mettler D; Scholl B; Magnusson L; Ris HB
    Lasers Surg Med; 2003; 32(1):61-8. PubMed ID: 12516073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.